Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
[Needham, MA] – June 10, 2025 – Perceptive Discovery, a leader in preclinical imaging and radiochemistry innovation, is pleased to announce the appointment of Sangeetha Palakurthi, Ph.D. as Senior Vice President of Oncology.
Dr. Palakurthi brings deep scientific leadership and translational oncology expertise to strengthen Perceptive’s position as the go-to partner for oncology drug development.
Dr. Palakurthi joins Perceptive with a distinguished career spanning biotech, pharmaceutical and academia. As a founding team member in multiple biotech companies, she successfully led programs from discovery through to early clinical development. Her appointment marks a strategic investment in building Perceptive’s best-in-class oncology offering—integrating deep domain expertise in radiochemistry with cutting-edge oncology insights.
“Perceptive is well known for its radiochemistry expertise. With Sangeetha on board, we’re poised to unlock our full potential in oncology. Her leadership will be instrumental in helping our clients accelerate from bench to bedside with deeper translational insights and greater scientific confidence.” said Ben Murphy, CEO at Perceptive Discovery.
As a scientist and strategist, Dr. Palakurthi brings:
“I’m excited to join Perceptive Discovery at a pivotal moment in its growth. The opportunity to integrate high-impact radiochemistry with oncology drug development has never been more important. I look forward to helping our clients navigate this path with speed, rigor, and innovation.” said Dr. Palakurthi.
Dr. Palakurthi’s appointment reflects Perceptive’s ongoing commitment to deliver integrated, science-driven support across oncology R&D—empowering biopharma teams to move smarter, faster, and with greater confidence into the clinic.
About Perceptive Discovery
Perceptive is a leading global technology-enabled service provider of preclinical and clinical trial imaging, clinical event adjudication, and IRT/RTSM (Interactive Response Technology/Randomized Trial Supply Management) for drug developers and the global clinical research community. Perceptive’s market-leading service, scientific knowledge, expertise, and technology offering help speed up the delivery of life-saving treatments to millions of patients around the world by accelerating and improving clinical trial outcomes. With operations in the US, Europe, the UK and Asia, the company provides 24/7 services to most of the world’s leading pharma and biotech companies.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
